News Desk — February 7, 2018 at 1:45 pm — Updated: February 7, 2018 at 1:45 pm

GSK cautious on 2018, as drug competition looms, after fourth quarter beats

by

LONDON (Reuters) – GlaxoSmithKline said on Wednesday its earnings could slip this year, after a better-than-expected performance in the fourth quarter, as the drugmaker faces increased competition in its core respiratory and HIV businesses.

Leave A Comment Using Facebook (Website Comment Form Below)

Use the form below to post a comment via facebook

Leave a Reply

68 queries in 0.986 seconds.